A-095 A New CO2 Assay with Concentrated Reagent Having Superior Onboard Stability on Mindray BS-2800M Analyzer
J Wang,X Huang,M Jiang,J Dai
DOI: https://doi.org/10.1093/clinchem/hvae106.094
IF: 12.114
2024-10-27
Clinical Chemistry
Abstract:BackgroundMeasurement of total content of CO 2 in serum or plasma can be used to assist in the diagnosis of various acid-base disorders. There are small amounts (about 0.04%) CO 2 in the earth's atmosphere, or more in an enclosed clinical laboratory space. The environmental CO 2 could be dissolved into the CO 2 reagent continuously, in particular at lowered temperature when it is opened and stored on the system, which leads an impact on CO 2 assay performance. Presently, competitors mainly use additional inserts or with small opening of the reagent container to reduce the contact with air from reagent, to improve its onboard stability. Here, we designed a new CO 2 assay by optimizing the reagent formulation with a new protection mechanism to reduce the amount of CO 2 absorption to the reagent and improved its onboard stability. This study evaluated performances of the new CO 2 assay on Mindray BS-2800M analyzer.MethodsMindray CO 2 assay with concentrated reagent is based on PEPC (Phosphoenolpyruvate Carboxylase) enzymatic method. It is designed with an innovative mechanism of reagent formulations with a protective layer of chemical(s) on top of the reagent that prevents CO 2 from entering the reagent and reduced its impact to its on-board stability. The onboard stability was conducted with a constant reagent consumption mode to simulate as it in clinical lab use. The onboard study used two levels of Quality Control materials and serum pools. According to CLSI protocols, the following assay performances were evaluated: onboard stability, precision, method comparison, linearity, and interference.ResultsOn Mindray BS-2800M analyzer, Mindray CO 2 assay demonstrated an excellent onboard stability. With uncapped reagent on the system, the stability is for 21 days without recalibration, with less than ± 5% deviation from day zero. In parallel onboard stability studies, with Roche CO 2 reagent on Cobas c701 system, the relative deviation from day zero was found to be within ±10%; and other three manufacturers` results with deviation exceeded ±10% vs. day zero in 7 days. The linearity of Mindray CO 2 assay was determined as from 2.0 to 50.0 mmol/L. Our CO2 assay correlated well with Roche CO 2 on Cobas c701 (Mindray = 1.0032 * Roche - 0.0186, r≥0.99). The repeatability and with-lab CVs were ranged from 0.64% to 3.41%, respectively. There was no significant interference (<±10%), at CO 2 concentration of 15 mmol/L with bilirubin up to 60 mg/dL,hemolysate up to 800 mg/dL, Intralipid up to 1000 mg/dL, triglycerides up to 1000 mg/dL.ConclusionsOn Mindray BS-2800M analyzer, the new CO2 assay demonstrated a good ability against environmental CO2 inference in 21 days of onboard time. The new CO 2 assay also shown good performances in precision, correlation (accuracy) and anti-interference from endogenous substances. Therefore, we conclude that the new Mindray CO2 assay is suitable for routine clinical laboratory use.
medical laboratory technology